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SIRT1, a mammalian ortholog of yeast silent interaction regulator 2 (Sir2), is a 
NAD+-dependent histone III deacetylase. SIRT1 regulates various cellular processes, 
such as apoptosis, stress response, tumorigenesis, and metabolism. Tumor suppressor 
p53 is a main target for SIRT1. Under normal conditions, p53 is deacetylated by SIRT1, 
inactivated, and degraded by MDM2, the major ubiquitin E3 ligase. Under stress 
conditions (e.g., exposure to UV or etoposide), however, p53 is acetylated by p300/CBP, 
dissociated from MDM2 for stabilization, and activated, resulting in p53-mediated 
induction of cell cycle arrest or apoptosis. 
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Small ubiquitin-related modifier (SUMO) is an ubiquitin-like protein that is 
conjugated to a variety of cellular proteins. Like ubiquitin, SUMO is conjugated to 
target proteins by a three enzyme cascade system consisting of SUMO-activating E1 
enzyme (SAE1/SAE2), SUMO-conjugating E2 enzyme (Ubc9), and SUMO E3 ligases 
(PIASs). Conjugated SUMO can be removed by a family of Sentrin-specific proteases 
(SENPs). This reversible sumoylation process regulates diverse cellular processes, 
including transcription, nuclear transport, stability, and signal transduction.  
Deleted in breast cancer 1 (DBC1) is a tumor suppressor that plays crucial roles in 
the control of diverse cellular processes, including stress response and energy 
metabolism. DBC1 is a major inhibitor of SIRT1. Under DNA damage conditions, 
DBC1 binds to SIRT1 and this tight binding displaces p53 from SIRT1, allowing 
acetylation and transactivation of p53 for expression of its downstream targets, such as 




Phosphorylation of DBC1 regulates DBC1-SIRT1 interaction and SIRT1 
deacetylase activity. Under stress conditions, ATM/ATR kinases are activated and 
phosphorylates DBC1 at Thr454. This phosphorylation causes tight binding between 
DBC1 and SIRT1, leading to dissociation of p53 from SIRT1 for subsequent acetylation 
and transactivation of p53. 
In this study, I demonstrated that DBC1 is a target for SUMO modification and that 
Lys591 serves as the major SUMO acceptor site. Treatment with DNA-damaging 
agents, such as etoposide and doxorubicin, induced sumoylation of endogenous DBC1. 
In addition, DBC1 was modified by SUMO2 and SUMO3, but not by SUMO1. 
Remarkably, this sumoylation of DBC1 promoted its interaction with SIRT1, leading 
to p53 acetylation.  
PIAS3 was found to act as a DBC1-specific SUMO E3 ligase and SENP1 was to 
serve as DBC1-specific desumoylation enzyme. Interestingly, PIAS3 and SENP1 
interacted to the same N-terminal region of DBC1 and therefore competed with each 
other for binding to DBC1. Etoposide treatment reduced the interaction of DBC1 with 
iv 
 
SENP1, but promoted that with PIAS3, resulting in an increase in DBC1 sumoylation. 
Remarkably, the switching from SENP1 to PIAS3 for DBC1 binding was achieved by 
ATM/ATR-mediated phosphorylation of DBC1. These results demonstrate that PIAS3 
and SENP1 antagonistically regulate SUMO modification of DBC1. Consistently, 
SENP1 knockdown promoted etoposide-induced apoptosis, whereas knockdown of 
PIAS3 or SUMO2/3 and overexpression of sumoylation-deficient DBC1 mutant 
inhibited it. Collectively, the present findings indicate that SUMO modification of 
DBC1 by SUMO2/3 plays a crucial role in p53-mediated apoptosis under DNA damage 
conditions. 
 
Key word: DBC1 (Deleted in brease cancer 1), p53, PIAS3 (protein inhibitor of 
activated STAT3), SENP1 (sentrin/sumo-specific protease 1), SUMO, phosphorylation, 
apoptosis 
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1. p53 pathway 
The p53 tumor suppressor has been regarded as “cellular gatekeeper” (Lane, 1992), 
as it coordinates cellular responses to various stress signals, such as DNA damage, 
abnormal oncogene activation, telomere erosion, and hypoxia (Green & Kroemer, 
2009). Under normal conditions, p53 is down-regulated by several ubiquitin E3 ligases, 
including the major MDM2 ligase, and subsequent degradation by proteasome. Notably, 
expression of MDM2 is induced by p53, thus forming a negative feedback loop for 
keeping p53 at a low level (Ashcroft & Vousden, 1999; Wu et al, 1993). Under stress 
conditions, however, p53 is stabilized and activated by disruption of its interaction with 
MDM2 or SIRT1 and the other negative regulators through phosphorylation by 
ATM/ATR kinases and acetylation by p300/CBP. The activated p53 then binds to a 








Figure 1. p53 pathway. 
Under normal conditions, p53 is deacetylated by SIRT1, inactivated, and degraded 
by E3 ligase MDM2 for proteasome. Under stress conditions, DNA damage activates 
various regulatory enzymes that can phosphorylate and acetylate p53. Phosphorylated 
and acetylated p53 is then dissociated from MDM2 for stabilization. The activated p53 















transcriptional activation of its target genes (e.g., CDKN1, BAX, and PUMA) that 
mediate cell cycle arrest and apoptosis (Miyashita & Reed, 1995). 
Since p53 is involved in the control of numerous critical cellular processes, its 
transactivity needs to be tightly regulated (Brooks & Gu, 2003). The p53 activity is 
regulated by a wide variety of post-translational modifications, including the 
modification by ubiquitin-like proteins, in addition to phosphorylation, methylation, 
acetylation, and ubiquitination. Whereas MDM2- and FBXO11-mediated neddylation 
inhibits p53-mediated transcriptional activation (Abida et al, 2007), sumoylation 
promotes it (Gostissa et al, 1999).  
 
2. SIRT1 
SIRT1, a mammalian ortholog of yeast silent information regulator 2 (Sir2), is a 
NAD+-dependent deacetylase (Imai et al, 2000). SIRT1 deacetylates a variety of cellular 
proteins, including histones, p53, PGC1, forkhead transcription factors, NF kB, Ku70, 
MyoD, and PPARr, implicating its important roles in the control of diverse cellular 
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processes, such as gene silencing, stress response, DNA repair, heterochromatin 
formation, and glucose metabolism (Chalkiadaki & Guarente, 2012; Qiang et al, 2012; 
Schwer & Verdin, 2008). In addition, SIRT1 was shown to extend the lifespan of yeast, 
Caenorhabditis elegans, and Drosophila (Lin et al, 2000; Wood et al, 2004), although 
this effect depends on the genetic background of the organisms (Burnett et al, 2011). 
Given the important physiological functions, the activity of SIRT1 is regulated by 
multiple mechanisms, including the cellular NAD+ level, the endogenous inhibitor 
nicotinamide (Bitterman et al, 2002), and post-translational modifications, such as 
phosphorylation and sumoylation (Kang et al, 2009). In addition, active regulator of 
SIRT1 (AROS) was shown to activate SIRT1 through protein-protein interaction (Kim 
et al, 2007). 
 
3. Small Ubiquitin-like Modifier (SUMO) 
The SUMO gene (SMT3) was initially identified in Saccharomyces cerevisiae in a 
genetic screen for suppressors of the centromeric protein Mif2. SUMO modification 
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(sumoylation) leads to covalent attachment of SUMO to specific lysine residues of 
target proteins (Kim et al, 2002; Yeh, 2009). Amino acids sequence of SUMO is 16% 
identical to ubiquitin sequence, but its three-dimensional structure almost completely 
overlaps with that of ubiquitin. Isoforms of the SUMO family are present in yeast, plants, 
and metazoan. The SUMO family in metazoan consist of four related proteins, SUMO1 
(also known as PIC1, Ubl1, GMP1, sentrin, Smt3c or hSmt3), SUMO2 (sentrin2 or 
Smt3a), SUMO3 (sentrin3 or Smt3b), and SUMO4. SUMO1-SUMO3 are ubiquitously 
expressed, whereas SUMO4 is expressed in the kidney, lymph node and spleen. 
SUMO2 and SUMO3 have 95% identical sequence, but SUMO1 shows about 50% 
amino acid sequence identity with SUMO2 and SUMO3. SUMOs, like ubiquitin, have 
the two conserved glycine residues in their C termini, which are crucial for conjugation 
to target proteins. SUMOs are synthesized as precursor proteins with extensions of 2-
11 amino acids, which need to be cleaved off for exposing the C-terminal glycine 
residues. 
Sumoylation of proteins, like ubiquitination, is catalyzed by a cascade enzyme 
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system, consisting of a hetero-dimeric SUMO-activating E1 enzyme (Uba1/Aos1), a 
SUMO-conjugating E2 enzyme (Ubc9), and SUMO E3 ligases (PIAS family) (Kim et 
al, 2002). Three proteins have been shown to have SUMO E3 ligase activity: RanBP2, 
the PIAS family, and the polycomb group protein Pc2. RanBP2 and the PIAS family 
interact with SUMO E2-conjugating enzyme Ubc9, and promote transfer of SUMO 
from Ubc9 to target proteins (Johnson, 2004) (Figure 2). Conjugated SUMO can be 
eliminated by a family of SUMO-specific proteases (SENPs). SUMO-specific 
proteases are cysteine proteases that possess a conserved catalytic domain characterized 
by the catalytic triad (histidine, aspartate and cysteine) and a conserved glutamine 
residue required for the formation of the oxyanion hole in the active site 
(Mukhopadhyay & Dasso, 2007; Yeh, 2009). Yeast has a single SUMO-like modifier, 
Smt3, and two Smt3-specific proteases, Ulp1 and Ulp2. The human SENPs can be 
divided into three families. The first family includes SENP1 and SENP2, which have 









Figure 2. SUMO modification pathway. 
SUMO1-3 are conjugated to target proteins by a cascade enzyme system, consisting 
of E1 SUMO-activating enzyme Uba1/Aos1, E2 SUMO-conjugating enzyme Ubc9, 
and SUMO E3 ligases, such as the PIAS family. This process can be reversed by 
















 The second family including SENP3 and SENP5 favors SUMO2/3 as substrates, and 
are enriched in the nucleolus. They are required for mitochondrial fission and fusion. 
The last family contains SENP6 and SENP7. These desumoylating enzymes participate 
in the control of diverse cellular processes, including transcription, signal transduction, 




Deleted in Breast Cancer-1 (DBC1) initially cloned from a region (8p21) 
homozygously deleted in breast cancer. As its name implies, DBC1 functions as a tumor 
suppressor. It also regulates mRNA splicing with ZIRD. DBC1 has a four functional 
domain. The N-terminal NLS domain of DBC1 mediates its nuclear localization and 
the leucine zipper domain mediates its interaction with SIRT1 (Kim et al, 2008; Zhao 
et al, 2008) (Figure 3). DBC1 also has an EF hand domain for calcium binding and a 








Figure 3. Domains of DBC1 protein. 
NLS (nuclear localization signal) mediates to nuclear localization. Luecine zipper 
domain is required for interaction with SIRT1. EF hand domain regulates calcium 

























DBC1 interacts with SIRT1, and forms a stable complex (Kim et al, 2008; Zhao et 
al, 2008). DBC1 overexpression in human cells represses SIRT1 activity, leading to an 
increase in p53 acetylation. Thus, DBC1 plays a critical role in promotion of p53- 
mediated apoptosis by acting as a specific inhibitor of SIRT1. DNA damage, such as 
etoposide, induces phosphorylation of DBC1 on Thr454 by ATM (ataxia telangiectasia-
mutated) and ATR (ataxia telangiectasia and Rad3-related) kinases (Yuan et al, 2012; 
Zannini et al, 2012). Phosphorylated DBC1 binds to and inhibits SIRT1, resulting in 
dissociation of the p53-SIRT1 complex and subsequent stimulation of p53 acetylation 
and p53-mediated apoptosis. 
 
5. Purpose of thesis work 
p53, a major tumor suppressor, is the first nonhistone protein found to be acetylated. 
The lysine residues that are acetylated also serve as the sites for ubiquitination and 
sumoylation, indicating the critical role of these modifications in the control of p53 
function as a transcription factor. Under normal conditions, p53 is deacetylated by 
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SIRT1 and is degraded by MDM2 E3 ligase. However, DNA damage triggers 
dissociation of p53 from SIRT1, leading to the acetylation, stabilization, and 
upregulation p53-mediated function. 
DBC1, as a major inhibitor of SIRT1, plays critical roles in the control of diverse 
cellular processes, including stress response and energy metabolism. DNA damage 
induces interaction of DBC1 with SIRT1 and finally displaces p53 from SIRT1. It 
triggers acetylation of p53 for induction of apoptosis. DBC1 is phosphorylated at 
Thr454 by ATM/ATR kinases and this phosphorylation regulates interaction of DBC1 
with SIRT1. However, it has been reported that phosphorylation-mimic mutant of 
DBC1 is insufficient in increasing DBC1-SIRT1 interaction (Zannini et al, 2012). Thus, 
this study aims to elucidate the mechanism how the interaction of DBC1 with SIRT1 is 
regulated in response to DNA damage. Notably, many proteins involved in DNA-
damage response are modified by SUMO (Altmannova et al, 2010; Dou et al, 2010; 
Lee et al, 2006; Lee et al, 2012) 2012). Therefore, it is important to determine whether 
SUMO modification is involved in the control of DBC1 function. In summary, the 
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purpose of this study is to clarify the molecular mechanism that controls the interaction 
of DBC1 with SIRT1 in response to DNA damage and to determine the relationship 







DBC1 was initially identified as a putative tumor suppressor, since its gene was 
found in a region frequently deleted in breast cancers. Intriguingly, DBC1 was later 
found to be a negative regulator of SIRT1 (Kim et al, 2008; Zhao et al, 2008). DBC1-
mediated inhibition of SIRT1 leads to an increase in p53 acetylation and thereby the 
p53-mediated processes, such as apoptosis. On the other hand, down-regulation of 
DBC1 results in SIRT1-mediated p53 deacetylation and inhibition of stress-induced 
apoptosis. Moreover, by using DBC1 knockout mice, DBC1 was shown to act as a 
major regulator of SIRT1 in vivo (Escande et al, 2010). 
DBC1 inhibits SIRT1 by direct binding to its deacetylase core and disrupting its 
interaction with substrates (Kim et al, 2008; Zhao et al, 2008). Recently, a C-terminal 
region that is essential for SIRT1 activity (called ESA) was shown to interact with the 
catalytic core (Kang et al, 2011). Therefore, it was proposed that DBC1 competes with 
the ESA region for interacting with the deacetylase core, leading to inhibition of SIRT1. 
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DBC1 may also regulate SIRT1 activity by sensing NAD+ through its catalytically 
inactive Nudix hydrolase (MutT) domain, which is known to bind NAD+ and ADP-
ribose (Anantharaman & Aravind, 2008). 
The interaction between SIRT1 and DBC1 appears to be dynamically regulated. 
Starvation leads to a decrease in the SIRT1-DBC1 interaction, resulting in an increase 
in SIRT1 activity in the liver of mice, and this effect on SIRT1 activity can be revered 
upon feeding with high-fat diet (Escande et al, 2010). Interestingly, activation of 
cAMP/PKA pathway causes dissociation of the SIRT1-DBC1 complex in an AMPK-
dependent fashion, suggesting that AMPK-mediated phosphorylation of SIRT1 and 
DBC1 may negatively regulate their binding (Nin et al, 2012). Conversely, ATM/ATR-
mediated phosphorylation of DBC1 increases its interaction with SIRT1 in response to 
genotoxic stress, leading to promotion of p53 acetylation and cell death (Yuan et al, 
2012; Zannini et al, 2012). 
SUMO is an ubiquitin-like protein that is conjugated to a variety of cellular proteins. 
Like ubiquitin, SUMO is conjugated to target proteins by a 3-step enzyme system: E1 
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SUMO activating enzyme (SAE1/SAE2), E2 SUMO conjugating enzyme (Ubc9), and 
SUMO E3 ligases (e.g., PIASs) (Capili & Lima, 2007; Kerscher et al, 2006; Rytinki et 
al, 2009). Conjugated SUMO can be removed by a family of SUMO-specific proteases 
(SENPs) (Mukhopadhyay & Dasso, 2007; Yeh, 2009). This reversible sumoylation 
process participates in the control of various cellular processes, including transcription, 
nuclear transport, and signal transduction (Gareau & Lima, 2010; Geiss-Friedlander & 
Melchior, 2007; Hay, 2005; Johnson, 2004; Kim et al, 2002). Moreover, sumoylation 
has been implicated in the control of DNA damage response (Altmannova et al, 2010; 
Bergink & Jentsch, 2009; Cremona et al, 2012; Dou et al, 2010; Hoege et al, 2002; Lee 
et al, 2006; Polo & Jackson, 2011; Psakhye & Jentsch, 2012; Sudharsan & Azuma, 
2012). For example, hnRNP-K, a coactivator of p53, is sumoylated in response to DNA 
damage and this modification leads to hnRNP-K stabilization and p53-mediated cell 
cycle arrest (Lee et al, 2012; Moumen et al, 2005). 
In the present study, I demonstrated that genotoxic stress induces the modification 
of DBC1 at Lys591 by SUMO2/3, but not by SUMO1. I also identified PIAS3 as a 
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DBC1-specific SUMO E3 ligase and SENP1 as a desumoylating enzyme for DBC1. 
Etoposide treatment markedly decreased the interaction of DBC1 with SENP1, whereas 
it promoted that with PIAS3. Remarkably, the switching of the binding partners of 
DBC1 was achieved by ATM/ATR-mediated phosphorylation of DBC1. Moreover, 
DBC1 sumoylation caused a dramatic increase in the DBC1-SIRT1 interaction, which 
led to the release of p53 from SIRT1 for transcriptional activation. Knockdown of 
SENP1 promoted etoposide-induced apoptosis, whereas that of SUMO2/3 or PIAS3 
and overexpression of sumoylation-deficient DBC1 mutant inhibited it. Collectively, 
these results indicate that DBC1 sumoylation plays a crucial role in the control of p53-








MATERIALS AND METHODS 
 
1. Plasmids and shRNAs 
The cDNA of DBC1 was cloned into pcDNA-HisMax and pCMV2-Flag. shRNAs 
were purchased from Open Biosystems. Target sequences for shRNAs are as follows: 
shPIAS3, 5’-GCTGTCGGTCAGACATCATTT-3’; shSENP1, 5’-CAAAGATATTC 
AAACTCTA-3’. shSUMO2/3, 5’-TCAATGAGGCAGATCAGATTC-3’. 
 
2. Cell culture and transfection 
HEK293T, U2OS, and HeLa cells were grown at 37°C in DMEM supplemented with 
100 units/ml penicillin, 1 mg/ml streptomycin, and 10% FBS. All transfections were 






3. Assays for SUMO modification 
HisMax-DBC1, Flag-SUMO3, and Flag-Ubc9 were overexpressed in HEK293T 
cells with or without Myc-tagged PIAS3 or SENP1. After culturing for 40 h, cells were 
lysed by boiling for 10 min in 150 mM Tris-HCl (pH 8), 5% SDS, and 30% glycerol. 
Cell lysates were diluted 20-fold with buffer A [20 mM Tris-HCl (pH 8.0), 150 mM 
NaCl, 1% Triton X-100, 1X protease inhibitor cocktail (Roche)] containing 10 mM 
imidazole and 2 mM NEM. After incubating them with Ni2+-NTA-agarose for 2 h at 
4°C, the resins were collected, washed with buffer A containing 20 mM imidazole, and 
boiled in SDS-sampling buffer. Supernatants were subjected to SDS-PAGE followed 
by immunoblot analysis. For assaying sumoylation of endogenous DBC1, HeLa cells 
treated with and without etoposide were lysed as above. Cell lysates were diluted 20-
fold with buffer B [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1 mM EDTA, and 1X 
protease inhibitor cocktail] containing 0.2% Triton X-100 and 4 mM NEM. The 
samples were incubated with anti-DBC1 antibody for 2 h at 4°C and then with protein-
A-Sepharose for the next 2 h. The resins were collected, washed with buffer B 
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containing 1% Triton X-100, and boiled. Supernatants were subjected to SDS–PAGE 
followed by immunoblot analysis. 
 
4. Immunoprecipitation 
Cell lysates were prepared in buffer B containing 1% Triton X-100 and 2 mM NEM. 
Cell lysates were incubated with appropriate antibodies for 2 h at 4°C and then with 
protein A-conjugated Sepharose for the next 1.5 h. Supernatants were subjected to SDS-
PAGE followed by immunoblot analysis. 
Antibodies against p53 (catalog #: DO-1), GAPDH (2D4A7), Ubc9 (N-15), DBC1 
(H-2), and SENP1 (C-12) were purchased from Santa Cruz. Anti-acetyl p53 (Millipore, 
04-1146), anti-DBC1 (Bethyl, A300-434A), anti-Flag M2 (Sigma-Aldrich, 1804) were 
also used. Anti-Xpress (1405573), anti-SUMO-1 (381900), anti-SUMO2/3 (51-9100) 
were purchased from Invitrogen. Anti-PIAS3 (4164S), anti-cleaved caspase-9 (7237S), 
and anti-cleaved PARP-1 (9541) were purchased from Cell signaling. For immunoblot 
analysis, all antibodies were diluted 1,000 fold in 3% BSA solution, except anti-Xpress 
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and Flag M2 antibodies were diluted 5,000 fold. 
 
5. SIRT1 activity assay 
The deacetylase activity of SIRT1 was determined by using a SIRT1 Activity Assay 
Kit (Abcam: catalog # ab156065) as recommended by the manufacturer. Briefly, cells 
were washed with cold PBS, lysed in buffer B containing 0.2% Triton X-100, and 
incubated on ice for 5 min. Cell lysates were treated with anti-SIRT1 antibody for 2 h 
at 4°C and then with protein A-conjugated Sepharose for the next 1.5 h. Precipitates 
were incubated with Fluoro-Substrate Peptide Solution, NAD+, and SIRT1 Assay 
Buffer. Fluorescence intensity was then measured using a microtiter plate fluorometer 
with excitation at 350 nm and emission at 450 nm. 
 
6. Determination of NAD+/NADH ratio 
Intracellular NAD+/NADH ratio was determined by using the NAD+/NADH 
Quantification Colorimetric Kit (BioVision: catalog # K337-100) as recommended by 
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the manufacturer. Briefly, cells were washed with ice-cold PBS, and disrupted by 
freezing-and-thawing. After centrifugation, one-half of the extracts were subjected to 
quantification of the total amount of NAD+ plus NADH by using appropriate buffers 
and reagents provided by the manufacturer. The other half was heated at 60°C for 30 
min to decompose NAD+, followed by determination of the amount of heat-stable 
NADH. The ratio of NAD+/NADH was then calculated by subtracting the amount of 
NADH from the total amount of NAD+ plus NADH and then divided by the amount of 
NADH. 
 
7. Purification of SUMO3, sumoylated DBC1, and SIRT1 
To purify SUMO3, Flag-SUMO3 was expressed in HEK293T cells. Cell lysates 
were incubated with anti-Flag- Sepharose (Sigma) for 2 h. The beads were collected, 
incubated with Flag peptides (Sigma) for 30 min, and centrifuged. The supernatants 
were used as the purified SUMO3. To obtain sumoylated DBC1, HisMax-DBC1, Flag-
SUMO3, and Myc-Ubc9 were expressed in HEK293T cells. Cell lysates were then 
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treated as above. The proteins eluted from the beads by Flag peptides were incubated 
with NTA-resins for 2 h. The resins were collected, incubated with PBS containing 200 
mM imidazole for 30 min, and centrifuged. The supernatants were used as the purified 
SUMO3-conjugated DBC1. To purify SIRT1, GST-SIRT1 was expressed in E. coli 
(BL21). Cell extracts were incubated with glutathione- Sepharose (GE). The beads were 
collected, incubated with glutathione. The supernatants were used as the purified GST-
SIRT1. All protein purifications were carried out at 4°C. 
 
8. Luciferase assay 
HeLa cells transfected with pcDNA-β-Gal and PG13-Luc or BAX-Luc were 
incubated for 48 h. After etoposide treatment, cells were cultured for 30 h, harvested, 
and assayed for luciferase. The enzyme activity was measured in a luminometer and 





9. TUNEL assay 
After treatment with etoposide, HeLa cells were perrmeabilized by incubation in a 
solution containing 0.1% sodium citrate and 0.1% Triton X-100 for 30 min at 65°C. 
After extensive washing, samples were further incubated in the TUNEL reaction 















DBC1 is a target for sumoylation 
The consensus sequence for sumoylation is Ψ-Lys-X-Glu/Asp, where Ψ is a large 
hydrophobic amino acid and X is any amino acid (Johnson, 2004). Upon sequence 
analysis, human DBC1 was found to have three potential sumoylation sites: Lys591, 
Lys667, and Lys839 (Figure 4). Therefore, I first examined whether DBC1 can be 
sumoylated upon overexpression of three SUMO isoforms. Interestingly, DBC1 was 
modified by SUMO2 and SUMO3, but not by SUMO1 (Figure 5). To identify the 
SUMO acceptor site(s) in DBC1, each of the Lys residues was substituted by Arg. The 
K591R mutation, but not the others, completely prevented DBC1 sumoylation (Figure 
6), indicating that Lys591 serves as the major SUMO acceptor site. Since SUMO2 and 
SUMO3 show more than 95% identity in their amino acid sequences, I used shRNAs 
directed to their identical nucleotide sequence for knocking down both of them, but 
used only SUMO3 for overexpression. 
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DNA damage induces sumoylation of DBC1 and its interaction with SIRT1 
Since sumoylation has been implicated in DNA damage response (Lee et al, 2012; 
Sacher et al, 2006), I examined whether genotoxic stress induces DBC1 sumoylation. 
Treatment of U2OS cells with etoposide led to a dramatic increase in SUMO2/3-
modification of endogenous DBC1 (Figure 7). In contrast, little or no SUMO1-
conjugated DBC1 could be detected. Moreover, knockdown of SUMO2/3 by a 
SUMO2/3-specific shRNA (shSUMO2/3), but not by a nonspecific shRNA (shNS), 
abrogated etoposide-induced DBC1 sumoylation (Figure 8), indicating that DBC1 
serves as a target for modification by SUMO2/3 under genotoxic stress. 
Significantly, SUMO2/3 knockdown also prevented etoposide-induced p53 
acetylation (see Figure 8), raising a possibility that DBC1 sumoylation promotes the 
SIRT1-DBC1 interaction and in turn inhibits SIRT1-mediated deacetylation of p53. To 
test this possibility, I compared the abilities of DBC1 and its K591R mutant in the 
interaction with SIRT1. Etoposide treatment led to a dramatic increase in the interaction 
of SIRT1 with DBC1, but not with the K591R mutant (Figure 9). Furthermore, 
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knockdown of SUMO2/3 also led to a marked decrease in the DBC1-SIRT1 interaction 
as well as in p53 acetylation and this decrease could be reversed by complementation 
of shRNA-insensitive SUMO3 (Figure 10). I next examined whether the sumoylation-
mediated increase in the DBC1-SIRT1 interaction can indeed inhibit the deacetylase 
activity of SIRT1. Overexpression of SUMO2 or SUMO3, but not SUMO1, with Ubc9 
led to a marked increase in the ability of DBC1 to inhibit the SIRT1 activity (Figure 
11A). Under the same conditions, however, the NAD+/NADH ratio remained 
unchanged, indicating that the inhibition of the SIRT1 activity is not due to the 
availability of the SIRT1 substrate (Figure 11B). These results indicate that sumoylation 
of DBC1 is required for its interaction with and inhibition of SIRT1 and in turn for 
promotion of p53 acetylation under genotoxic stress. 
In an attempt to determine the mechanical basis for the preferential interaction of 
SIRT1 with sumoylated DBC1 over its unmodified form, I examined whether SIRT1 
has a SUMO-interacting motif (SIM), which consists of hydrophobic core and acidic 
stretch sequence franked by a spacer (Hecker et al, 2006; Song et al, 2004). Sequence 
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analysis showed that SIRT1 has a hydrophobic core sequence (IIVL), which is identical 
to that of Daxx, although it lacks an acidic stretch (Figure 12A). To determine whether 
the hydrophobic sequence is involved in the binding of SIRT1 to SUMO, I generated a 
SIRT1 mutant (KKVL), of which the first two Ile residues were replaced by Lys 
residues. SIRT1 bound to all of the SUMO isoforms, but this binding could be 
prevented by the II-to-KK mutation (Figure 12B), indicating that the hydrophobic core 
of SIRT1 is sufficient for interaction with SUMOs. In addition, purified SUMO3 could 
effectively compete with SUMO3-conjugated DBC1 for binding to SIRT1 (Figure 13). 
Furthermore, the II-to-KK mutation prevented the etoposide-mediated increase in the 
SIRT1-DBC1 interaction (Figure 14A). However, the II-to-KK mutation showed little 
or no effect on the ability of SIRT1 to deacetylate p53 (Figure 14B), indicating that the 
effect of the mutation on the SIRT1-DBC1 interaction is not mediated by misfolding or 
conformational change of SIRT1. These results demonstrate that the SIM-like sequence 




DBC1 sumoylation blocks interaction of SIRT1 with p53 
To determine whether DBC1 sumoylation influences the interaction between SIRT1 
and p53, HeLa cells overexpressing DBC1 and its K591R mutant were treated with 
etoposide. Overexpression of DBC1, but not its K591R mutant, markedly decreased the 
SIRT1-p53 interaction (Figure 15). Moreover, knockdown of SUMO2/3 led to an 
increase in the SIRT1-p53 interaction (Figure 16). Since SUMO2/3 knockdown 
reduced the DBC1-SIRT1 interaction (see Figure 10), it appeared that sumoylated 
DBC1, unlike its unmodified form, is capable of replacing p53 for its binding to SIRT1. 
To test this possibility, increasing amounts of SUMO3 were expressed with a fixed 
amount of DBC1 or its K591R mutant. The interaction of SIRT1 with DBC1 gradually 
increased, whereas that with p53 declined in a SUMO3 dose-dependent manner (Figure 
17). In contrast, SIRT1 was unable to interact with the K591R mutant, and remained 
bound to p53 regardless of SUMO3 expression. These results indicate that sumoylation 




PIAS3 and SENP1 counteract on SUMO modification of DBC1.  
To identify DBC1-specific SUMO E3 ligase, each of PIAS1-4 was overexpressed 
with DBC1. Among them, only PIAS3 interacted with DBC1 (Figure 18). Moreover, 
the DBC1-PIAS3 interaction was markedly increased by etoposide treatment (Figure 
19). I next examined whether PIAS3 is indeed capable of promoting DBC1 sumoylation. 
Overexpression of PIAS3 dramatically increased DBC1 sumoylation (Figure 20). On 
the other hand, knockdown of PIAS3 by shPIAS3 prevented sumoylation of 
endogenous DBC1 with a marked reduction in etoposide-induced SIRT1-DBC1 
interaction as well as in p53 acetylation (Figure 21). These effects of PIAS3 knockdown 
was confirmed by reciprocal immunoprecipitation analysis (Figure 22). Moreover, 
complementation of shRNA-insensitive PIAS3 reversed the effects of PIAS3 depletion 
on both the DBC1-SIRT1 interaction and p53 acetylation, indicating that PIAS3 serves 
as a SUMO2/3 E3 ligase for DBC1 and in turn as a positive regulator of p53.  
To map the regions for the PIAS3-DBC1 interaction, their deletions were generated 
(Figure 23A and B). DBC1 bound to the N-terminal region of PIAS3 (amino acids 1-
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200), and PIAS3 bound to the N-terminal region of DBC1 (1-243). In addition, the 
deletion of the leucine zipper motif (243-264), which is known to mediate the binding 
of DBC1 to SIRT1 (Kim et al, 2008), showed little or no effect on its binding to PIAS3. 
To identify DBC1-specific desumoylating enzyme, each of SENP1-3 and SENP5-7 
was overexpressed with DBC1. Note that SENP4, also called SUSP1, is expressed in 
rat and mice but not in human (Lee et al, 2006). Among the human SENPs, SENP1, 
SENP3, and SENP5 interacted with DBC1 (Figure 24). Without overexpression, 
however, only SENP1 interacted with DBC1 and this interaction was markedly reduced 
by etoposide treatment (Figure 25).  
To determine whether SENP1 is indeed capable of desumoylating DBC1, I 
generated a catalytically inactive mutant of SENP1 (C603S) by substituting the active 
site Cys603 residue by Ser. Overexpression of SENP1, but not its C603S mutant, led to 
complete desumoylation of DBC1 (Figure 26). On the other hand, SENP1 knockdown 
caused a marked increase in DBC1 sumoylation even in the absence of etoposide and 
this increase was further ameliorated in its presence (Figure 27). SENP1 knockdown 
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also led to an increase in the DBC1-SIRT1 interaction as well as in p53 acetylation and 
this increase was further elevated by etoposide treatment. These effects of SENP1 
depletion were confirmed by reciprocal immunoprecipitation analysis (Figure 28). 
Moreover, complementation of shRNA-insensitive SENP1 reversed the effects of 
SENP1 depletion on both the DBC1-SIRT1 interaction and p53 acetylation. These 
results indicate that SENP1 serves as a desumoylating enzyme for DBC1 and in turn as 
a negative regulator of p53. 
To map the regions for the SENP1-DBC1 interaction, their deletions were generated. 
DBC1 bound to the N-terminal region of SENP1 (amino acids 1-200) (Figure 29A). 
Significantly, SENP1 bound to the N-terminal region of DBC1 (1-243) (Figure 29B), 
where PIAS3 also binds (See Figure 23B). Consistently, SENP1 and PIAS3 were found 
to compete with each other for binding to DBC1 upon analysis by expression of 
increasing amounts of the one over the other (Figure 30). These results indicate that 
DBC1 sumoylation could be dynamically regulated by competitive binding of PIAS3 
and SENP1 to DBC1 under genotoxic stress. 
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DBC1 phosphorylation promotes its sumoylation 
ATM/ATR-mediated phosphorylation of Thr454 in DBC1 was shown to increase its 
interaction with SIRT1 (Yuan et al, 2012; Zannini et al, 2012). To determine whether 
the phosphorylation of DBC1 influences its sumoylation, phosphorylation-defective 
(T454A) and phosphorylation-mimicking (T454D) mutants were generated by 
substituting Thr454 with Ala and Asp, respectively. Overexpression of the T454D 
mutant dramatically increased DBC1 sumoylation, whereas that of the T454A mutant 
decreased it (Figure 31). Moreover, the T454D mutation increased the ability of 
sumoylated DBC1 to bind SIRT1, whereas the T454A mutation decreased it. 
Furthermore, the T454D mutation promoted the DBC1-PIAS3 interaction, whereas the 
T454A mutation inhibited it (Figure 32). In contrast, the T454D mutation decreased the 
DBC1-SENP1 interaction, whereas the T454A mutation increased it. Consistently, 
treatment with caffeine, an ATM/ATR inhibitor, prevented the etoposide-induced 
association and dissociation of DBC1 with PIAS3 and SENP1, respectively (Figure 33). 
These results indicate that ATM/ATR-mediated DBC1 phosphorylation serves as a 
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switch of DBC1-binding partner from SENP1 to PIAS3 for DBC1 sumoylation, which 
in turn promotes the DBC1-SIRT1 interaction for p53 acetylation under genotoxic 
stress. 
 
DBC1 sumoylation is required for p53 transactivation 
To determine whether DBC1 sumoylation leads to transcriptional activation of p53 
by sequestering SIRT1 from p53, two reporter vectors, PG13-LUC and BAX-LUC, were 
employed. Etoposide treatment increased the luciferase activity and this increase was 
further elevated by overexpression of DBC1, but not by that of the K591R mutant 
(Figure 34). Moreover, knockdown of SUMO2/3 or PIAS3 abrogated etoposide-
induced p53 transactivity regardless of co-knockdown of DBC1 (Figure 35). In contrast, 
knockdown of SENP1 further increase the drug-induced p53 transactivity and this 
increase was abrogated by co-knockdown of DBC1 (Figure 36). These results indicate 




DBC1 sumoylation is required for p53-mediated apoptosis 
To determine whether DBC1 sumoylation-mediated p53 activation is responsible for 
DNA damage-induced apoptosis, I generated HeLa cells that stably express shNS or 
shDBC1. As expected, DBC1 knockdown prevented etoposide-mediated increase in 
the cleavage of PARP-1 and caspase-9 and the level of acetylated p53 (Figure 37). 
However, complementation of shRNA-insensitive DBC1, but not the K591 mutant, led 
to a significant increase in both of them in the presence of etoposide, but not in its 
absence. Knockdown of SENP1 also increased the cleavage of PARP-1 and caspase-9 
and the level of acetylated p53 and this increase could be abrogated by co-knockdown 
of DBC1 (Figure 38). On the other hand, knockdown of SUMO2/3 or PIAS3 prevented 
both of them and these effects could be reversed by co-expression of shRNA-insensitive 
SUMO3 or PIAS3, respectively (Figure 39). Consistently, overexpression of DBC1, but 
not the K591R mutant, markedly increased the number of TUNEL-positive apoptotic 
cells (Figure 40). Whereas knockdown of SUMO2/3 or PIAS3 decreased the number 
of apoptotic cells, that of SENP1 increased the number and this increase was abrogated 
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by co-knockdown of DBC1 (Figure 41). These results indicate that DBC1 sumoylation 
is a crucial step for p53-mediated apoptosis under genotoxic stress. 
I next examined whether the removal of etoposide from media could reverse the 
drug-induced DBC1 sumoylation and apoptosis. Withdrawal of etoposide from culture 
media at 48 h led to a sharp decrease in the levels of sumoylated DBC1, p53, and 
acetylated-p53 (Figure 42). On the other hand, the levels of cleaved PARP-1 and 
caspase-9 remained elevated, although did not increase any further. These results 
















Figure 4. Consensus sequence for DBC1 sumoylation. 






























Figure 5. DBC1 is modified by SUMO2/3, but not by SUMO1. 
Flag-tagged SUMO isoforms were expressed in HEK293T cells with HisMax-DBC1 
and Myc-Ubc9. Cell lysates were subjected to pull-down (PD) with NTA-resins 
























Figure 6. Lys 591 is the major SUMO acceptor site in DBC1. 
HisMax-tagged DBC1 and its K-to-R mutants were expressed in HEK293T cells 
with Flag-SUMO3 and Flag-Ubc9. Cell lysates were subjected to pull-down with NTA-
























Figure 7. Etoposide induces DBC1 sumoylation. 
U2OS cells were treated with 20 μM etoposide (ETO) for increasing periods. Their 
lysates were subjected to immunoprecipitation (IP) with anti-DBC1 antibody followed 
by immunoblot analysis. Cell lysates were also directly probed with anti-acetylated p53 
























Figure 8. Knockdown of SUMO2/3 blocks etoposide-induced DBC1 sumoylation. 
U2OS cells expressing nonspecific shRNA (shNS) or shSUMO2/3 were incubated 
with and without etoposide for 36 h. Their lysates were then subjected to 
























Figure 9. Etoposide increases interaction of SIRT1 with DBC1, but not KR mutant. 
HeLa cells expressing Flag-tagged DBC1 (Wt) and its K591R mutant (KR) were 
incubated with and without etoposide for 36 h. Their lysates were subjected to 























Figure 10. Etoposide-induced sumoylation of DBC1 increases its interaction with 
SIRT1. 
HeLa cells expressing shNS or shSUMO2/3 were incubated for 36 h with and 
without Flag-SUMO3 in the presence and absence of etoposide. Their lysates were 
subjected to immunoprecipitation with anti-SIRT1 antibody followed by immunoblot 





















Figure 11. Effects of DBC1 sumoylation on the SIRT1 activity and the 
NAD+/NADH ratio. 
(A) Myc-SIRT1 and Flag-Ubc9 were expressed in HEK293T cells with and without 
HisMax-DBC1 and/or each of SUMO isoforms. The deacetylase activity of SIRT1 was 
then assayed as described under Materials and Methods. The SIRT1 activity seen only 
with Myc-SIRT1 and Flag-Ubc9 was expressed as 100% and the others were as its 
relative values. Error bar, ±  s.d. (n=3). (B) The cells were also subjected to 
determination of the NAD+/NADH ratio. The NAD+/NADH ratio seen only with Myc-
SIRT1 and Flag-Ubc9 was expressed as 1.0 and the others were as its relative values. 














Figure 12. SIRT1 has a SIM-like sequence. 
(A) The SUMO-interacting motifs (SIMs) of PML and Daxx were compared with a 
similar sequence in SIRT1. Two lle residues in the hydrophobic core (HC) sequence of 
SIRT1 were replaced by two Lys residues. ‘S’ and ‘AS’ indicate spacer and acidic 
stretch sequences, respectively. There are scheme of SIM-like sequence in SIRT1 
protein. (B) Flag-tagged SUMO isoforms were expressed in HEK293T cells with Myc-
tagged SIRT1 or its KKVL mutant. Cell lysates were subjected to immunoprecipitation 























Figure 13. Competition of SUMO3 with SUMO3-conjugated DBC1 for binding to 
SIRT1. 
Purified Flag-SUMO3-conjugated HisMax-DBC1 and GST-SIRT1 proteins were 
incubated with increasing amounts of purified Flag-SUMO3 for 2 h at 4°C. The 
samples were then subjected to immunoprecipitation with anti-GST antibody followed 























Figure 14. SIM-like sequence of SIRT1 is essential for its binding to sumoylated 
DBC1. 
(A) HisMax-DBC1 was expressed in HeLa cells with Myc-tagged SIRT1 or its 
KKVL mutant, and incubated with and without etoposide for 36 h. Cell lysates were 
subjected to pull-down with NTA-resins followed by immunoblot analysis. (B) 
HisMax-p53 and Flag-p300 were expressed in HeLa cells with Myc-tagged SIRT1 or 























Figure 15. DBC1, but not KR mutant, blocks the interaction of SIRT1 with p53. 
HeLa cells expressing Flag-tagged DBC1 (Wt) or its K591R mutant (KR) were 
incubated with etoposide for 36 h. Their lysates were subjected to immunoprecipitation 


























Figure 16. Knockdown of SUMO2/3 increases the interaction of SIRT1 with p53. 
HeLa cells expressing shNS or shSUMO2/3 were incubated with etoposide for 36 h. 
Their lysates were subjected to immunoprecipitation with anti-p53 antibody followed 


























Figure 17. SUMO3 increases interaction of DBC1 with SIRT1, but not by KR 
mutant. 
HisMax–DBC1 or its K591R mutant, Flag-Ubc9, HA-p53 and Myc-SIRT1 were 
expressed in HEK293T cells with increasing amounts of Flag-SUMO3. Cell lysates 























Figure 18. PIAS3 specifically interacts with DBC1 among PIAS family. 
HisMax-DBC1 was expressed in HEK293T cells with each of Flag-tagged PIAS1-4. 
Cell lysates were subjected to immunoprecipitation with anti-Flag antibody followed 


























Figure 19. Etoposide induces interaction of PIAS3 with DBC1. 
HeLa cells incubated with and without etoposide for 36 h were subjected to 

























Figure 20. Overexpression of PIAS3 increases DBC1 sumoylation. 
Flag-tagged SUMO3 and Ubc9 were expressed in HEK293T cells with HisMax-
DBC1 and/or Myc-PIAS3. Cell lysates were subjected to pull-down with NTA-resins 
























Figure 21. Knockdown of PIAS3 prevents sumoylation of DBC1 with a reduction 
in etoposide-induced SIRT1-DBC1 interaction. 
HeLa cells expressing shNS or shPIAS3 were incubated with and without etoposide 
for 36 h. Their lysates were subjected to immunoprecipitation with anti-DBC1 antibody 






















Figure 22. Knockdown of PIAS3 prevents etoposide-induced DBC1-SIRT1 
interaction. 
shNS and shPIAS3 were expressed in HeLa cells with and without Myc-PIAS3. 
After incubation with and without etoposide for 36 h, cell lysates were subjected to 
immunoprecipitation with anti-SIRT1 antibody followed by immunoblot analysis. ‘i’ 






















Figure 23. Mapping the regions for the interaction between PIAS3 and DBC1. 
(A) Deletions of PIAS3 were generated, tagged with HisMax to their N-termini, and 
expressed in HEK293T cells with Flag-DBC1. Cell lysates were subjected to pull-down 
with NTA resins followed by immunoblot analysis. (B) Deletions of DBC1 were 
generated, tagged with Flag to their N-termini, and expressed in HEK293T cells with 
Myc-PIAS3. Cell lysates were subjected to immunoprecipitation with anti-Flag 


















Figure 24. Interaction of SENPs with DBC1 under overexpression condition. 
HisMax-DBC1 was expressed in HEK293T cells with each of SENP1, 2, 5 and 7 or 
SENP3 and 6. Cell lysates were subjected to immunoprecipitation with anti-Myc and 

























Figure 25. Etoposide decreases interaction of SENP1 and DBC1. 
HeLa cells incubated with and without etoposide for 36 h were subjected to 
























Figure 26. Overexpression of SENP1, but not its C603S mutant, leads to complete 
desumoylation of DBC1. 
HisMax-DBC1, Flag-Ubc9 and Flag-SUMO3 were expressed in HEK293T cells 
with Myc-tagged SENP1 or its C603S mutant. Cell lysates were subjected to pull-down 























Figure 27. Knockdown of SENP1 increases etoposide-induced DBC1 sumoylation 
and interaction between DBC1 and SIRT1. 
HeLa cells expressing shNS or shSENP1 were incubated with and without etoposide 
for 36 h. Their lysates were subjected to immunoprecipitation with anti-DBC1 antibody 























Figure 28. Complementation of shRNA-insensitive SENP1 reverses the effects of 
SENP1 depletion on the DBC1-SIRT1 interaction. 
shNS and shSENP1 were expressed in HeLa cells with and without Myc-SENP1. 
They were incubated with and without etoposide for 36 h. Cell lysates were subjected 
to immunoprecipitation with anti-SIRT1 antibody followed by immunoblot analysis. ‘i’ 






















Figure 29. Mapping the regions for the interaction between SENP1 and DBC1. 
(A) Deletions of SENP1 were generated, tagged with Myc to their N-termini, and 
expressed in HEK293T cells with Flag-DBC1. Cell lysates were subjected to 
immunoprecipitation with anti-Myc antibody followed by immunoblot analysis. (B) 
Deletions of DBC1 were generated, tagged with Flag to their N-termini, and expressed 
in HEK293T cells with Myc-SENP1. Cell lysates were subjected to 



















Figure 30. PIAS3 competes with SENP1 for binding to DBC1. 
Flag-DBC1 and Myc-SENP1 were expressed in HEK293T cells with increasing 
amounts of HisMax-PIAS3 (top). HisMax-DBC1 and Flag-PIAS3 were expressed with 
increasing amounts of Myc-SENP1 (bottom). Cell lysates were subjected to 
immunoprecipitation with anti-Flag antibody (top) and pull-down with NTA resins 





















Figure 31. DBC1 phosphorylation influences its sumoylation. 
Flag-tagged SUMO3 and Ubc9 were expressed in HEK293T cells with HisMax-
tagged DBC1, T454A or T454D. Cell lysates subjected to pull-down with NTA-resins 

























Figure 32. DBC1 phosphorylation switches its binding partner from SENP1 to 
PIAS3. 
shRNA-insensitive Flag-tagged DBC1, T454A or T454D was expressed in HeLa 
cells that had been stably transfected with shNS or shDBC1. Cell lysates were subjected 
























Figure 33. Caffeine blocks etoposide-induced DBC1 sumoylation and its 
interaction with SIRT1. 
HeLa cells were incubated with etoposide and caffeine for 36 h. Cell lysates were 























Figure 34. Overexpression of DBC1, but not KR mutant, increases p53 
transactivity. 
Flag-DBC1 (Wt) or its K591R mutant (KR) was expressed in HeLa cells with PG13-
LUC (top) and BAX-LUC (bottom). After incubation with and without etoposide for 36 
h, cells were subjected to assay for the luciferase activity. The activity seen without any 
treatment was expressed as 1.0 and the others were expressed as its relative values. 


















Figure 35. Knockdown of PIAS3 or SUMO2/3 blocks p53 transactivation. 
shNS, shDBC1, shPIAS3 or shSUMO2/3 was expressed in HeLa cells with PG13-
Luc (top) or BAX-Luc (bottom). After incubation with and without etoposide for 36 h, 
cells were subjected to assay for the luciferase activity. The activity seen without any 
treatment was expressed as 1.0 and the others were expressed as its relative values. 


















Figure 36. Knockdown of SENP1 increases p53 transactivation. 
shNS or shDBC1 and/or shSENP1 was expressed in HeLa cells with PG13-Luc (top) 
or BAX-Luc (bottom). After incubation with and without etoposide for 36 h, cells were 
subjected to assay for the luciferase activity. The activity seen without any treatment 



















Figure 37. Overexpression of DBC1, but not by KR mutant, increases p53-
mediated apoptotic genes. 
shRNA-insensitive Flag-tagged DBC1 or its K591R mutant was expressed in HeLa 
cells that had been stably transfected with shNS or shDBC1. After incubation with and 
without etoposide for 36 h, they were subjected to immunoblot with anti-DBC1, anti-
























Figure 38. Knockdown of SENP1 increases p53-mediated apoptotic genes. 
shNS or shDBC1 was expressed in HeLa cells with or without shSENP1. Cells were 
then incubated in the presence and absence of etoposide for 36 h. Cell lysates were 
subjected to immunoblot with anti-DBC1, anti-SENP1, anti-acetyl p53, anti-cleaved 
























Figure 39. Knockdown of SUMO2/3 or PIAS3 decreases p53-mediated apoptotic 
genes. 
shSUMO2/3 or shPIAS3 was expressed in HeLa cells with Flag-SUMO3 or Myc-
PIAS3. After incubation with and without etoposide for 36 h, cell lysates were subjected 
to immunoblot with anti-DBC1, anti-SUMO2/3, anti-PIAS3, anti-acetyl p53, anti-





















Figure 40. Overexpression of DBC1, but not by KR mutant, increases the number 
of TUNEL-positive cells. 
HeLa cells expressing Flag-DBC1 or its K591R mutant were incubated with and 



























Figure 41. Knockdown of SUMO2/3 or PIAS3 decreases the number of TUNEL-
positive cells, but Knockdown of SENP1 increases it. 
shNS or shDBC1 was expressed HeLa cells with shNS, shSUMO2/3, shPIAS3, 
shSENP1. After incubation with and without etoposide, cells were then subjected to 
















Figure 42. Effects of etoposide withdrawal on DBC1 sumoylation and apoptosis. 
Etoposide was treated to HeLa cells for increasing periods up to 48 h. After the 
incubation, cells were further cultured for the next 36 h in fresh media in the absence of 
the drug. Cell lysates obtained at each time point were subjected to immunoprecipitation 






















Based on the present findings, I propose a model for the role of DBC1 sumoylation 
in the control of p53-mediated apoptosis in response to DNA damage (Figure 43). 
DBC1 is normally bound to SENP1. Under genotoxic stress, however, DBC1 becomes 
phosphorylated at Thr454 by the ATM/ATR kinases (Yuan et al, 2012; Zannini et al, 
2012) and this phosphorylation switches the binding partner of DBC1 from SENP1 to 
PIAS3, leading to its sumoylation. DBC1 sumoylation markedly increases the DBC1-
SIRT1 interaction and this tight binding displaces p53 from SIRT1, allowing acetylation 
(e.g., by p300) and transactivation of p53 for the expression of its downstream genes, 
such as BAX and PUMA, which induce apoptotic cell death. Interestingly, DBC1 was 
modified by SUMO2/3, but not by SUMO1, despite the fact that PIAS3 is capable of 
modifying other target proteins by SUMO1, such as hnRNP-K (Lee et al, 2012). 







Figure 43. A model for the role of DBC1 sumoylation in p53-mediated apoptosis 
in response to DNA damage. 
DBC1 is normally bound to SENP1. Under genotoxic stress, DBC1 is 
phosphorylated at Thr454 by the ATM/ATR kinases and this phosphorylation switches 
the binding partner of DBC1 from SENP1 to PIAS3, leading to its sumoylation. DBC1 
sumoylation increases the DBC1-SIRT1 interaction and this tight binding displaces p53 
from SIRT1, allowing acetylation and transactivation of p53 for the expression of its 



















that SUMO2/3 conjugated to DBC1 increases the affinity of the inhibitor protein to 
SIRT1. Collectively, post-translational modifications of DBC1 by the sequential actions 
of ATM/ATR kinases and PIAS3 play a crucial role in the control of the DBC1-SIRT1 
interaction for p53-mediated apoptosis under genotoxic stress. 
SUMO2/3, unlike SUMO1, is known to form poly-SUMO chains. However, DBC1 
was found to be modified by a single molecule of SUMO2/3 (mono-SUMO2/3-ylated), 
but not by its polymeric chain. Likewise, Drp1 and ROR alpha have been shown to be 
mono-SUMO2/3-ylated (Guo et al, 2013; Hwang et al, 2009). Thus, it seems likely that 
SUMO2/3 can be conjugated to target proteins not only as polymeric chain(s) but also 
as a single molecule, although it remains unknown how the chain length is regulated. 
Of interest was the finding that SENP1 and PIAS3 bind to the same N-terminal 
region of DBC1 and this competitive binding can be switched by ATM/ATR-mediated 
phosphorylation of DBC1. However, it remains unknown how the phosphorylation of 
DBC1 at Thr454, which is located distal to the binding region (the amino acids 1-243) 
of SENP1 and PIAS3, could influence the interaction of DBC1 with the SUMO-
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modifying enzymes. Possibly in the 3D structure of DBC1, Thr454 may be in close 
proximity to the binding site for SENP1 and PIAS3, and when the threonine residue is 
phosphorylated, the negative charge might provide a better structural atmosphere for 
the interaction of DBC1 with PIAS3, but not with SENP1. Recently, it has been reported 
that ATM-mediated phosphorylation of DBC1 at Thr454 provides a second binding site 
for SIRT1, leading to inhibition of the deacetylase activity (Yuan et al, 2012). Notably, 
DBC1 is capable of forming a ternary complex with PIAS3 and SIRT1 upon treatment 
with etoposide and this complex formation could be prevented by co-treatment with 
caffeine, an inhibitor of the ATM/ATR kinases (Figure 33). Thus, it appears possible 
that DBC1 phosphorylation plays a dual role: one in providing a second binding site for 
SIRT1 and the other in promotion of PIAS3 binding to DBC1 for sumoylation, which 
further increases the DBC1-SIRT1 interaction via the SIM-like sequence of the 
deacetylase. 
Significantly, it has been reported that SIRT1 can be modified by SUMO1 and this 
modification increases its deacetylase activity, leading to p53 inactivation and cell 
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survival (Yang et al, 2007). Under stress conditions, however, SENP1 inactivates SIRT1 
by desumoylation and in turn activates p53 for stress-induced apoptosis. Therefore, 
SIRT1 sumoylation was suggested to act as a molecular switch that tips the balance 
from survival to death when DNA is damaged (Yang et al, 2007), although it was not 
determined whether SIRT1 sumoylation influences its ability to interact with DBC1. 
Interestingly, the same SENP1 enzyme is utilized for desumoylation of both SIRT1 and 
DBC1, although the enzyme removes SUMO1 from SIRT1 and SUMO2/3 from DBC1. 
However, SENP1-mediated desumoylation of SIRT1 and DBC1 appears to oppositely 
impact on cell fate. Whereas the action of SENP1 on SIRT1 promotes stress-induced 
apoptosis by inactivating the deacetylase activity, its action on DBC1 allows cells to 
survive by inhibiting the DBC1-SIRT1 interaction under unstressed conditions. DBC1 
may sequester SENP1 from SIRT1 under normal conditions (Figure 25) and thereby 
SIRT1 would maintain its sumoylated state for p53 deacetylation. However, when 
DBC1 is phosphorylated in response to DNA damage, SENP1 bound to DBC1 would 
be replaced by PIAS3, and become available for desumoylation of SIRT1. 
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In conclusion, I demonstrated that the modification of DBC1 by SUMO2/3 
orchestrates with its ATM/ATR-mediated phosphorylation and SENP1-mediated 
removal of SUMO1 from SIRT1 for the control of the DBC1-SIRT1 interaction and in 
turn for p53-mediated apoptosis under genotoxic stress. Importantly, however, DBC1 
has also been implicated in promotion of cell proliferation (Kim et al, 2009). For 
example, DBC1 binds to ER alpha, but its knockdown in MCF7 breast cancer cells 
enhances apoptosis in the absence of estrogen, suggesting the role of DBC1 as a positive 
regulator of cell growth (Trauernicht et al, 2007). Furthermore, it has been shown that 
the mRNA level of DBC1 is up-regulated in breast cancers, although not in prostate 
cancers (Fu et al, 2009; Radvanyi et al, 2005; Richardson et al, 2006). Thus, it appears 
that DBC1 plays a pleiotropic role in the control of cell growth and death, which might 
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포유류에서 SIRT1은 효모의 silent information regulator2 와 
상동체로써, NAD+-의존 히스톤 탈아세틸화 효소활성을 보인다. SIRT1은 
세포사멸, 스트레스 반응, 암 생성 그리고 대사과정 등 세포 내 다양한 
반응을 조절한다. 대표적인 암 억제 인자인 p53이 SIRT1의 주요 
표적단백질이다. 스트레스가 가해지지 않은 환경에서는 p53은 SIRT1에 
의해서 탈아세틸화되어 비활성상태로 존재하여, E3 유비퀴틴결합효소인 
MDM2에 의해서 분해된다. 하지만 자외선이나 etoposide와 같은 
스트레스가 가해진 환경에서는, p53은 p300/CBP 아세틸화효소에 의해 
아세틸화되며, p53은 안정화되면서 활성화된다. 결국 활성화 및 안정화된 
p53은 세포주기 중지나 세포사멸을 유도한다. 
Small ubiquitin-related modifier (SUMO)는 유비퀴틴 유사 
단백질로서 세포 내 여러 표적단백질들과 결합한다. 유비퀴틴화 시스템과 
비슷하게, SUMO 또한 E1 활성 효소인 SAE1/SAE2와, E2 접합 효소인 
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Ubc9, 그리고 E3 결합효소인 PIASs들 효소에 의한 연속 전달 
시스템으로 표적 단백질에 접합된다. 표적 단백질에 결합된 SUMO는 
sentrin-specific proteases (SENPs)들에 의해서 반대로 제거될 수 있다. 
이러한 가역적인 수모화 과정은 전사조절, 핵으로의 이동, 단백질 안정화 
그리고 신호전달 과정 등 세포 내 다양한 프로세스를 조절한다.  
Deleted in breast cancer 1 (DBC1) 은 이름에서도 알 수 있듯이, 암 
억제인자로서 작용하며, 스트레스 반응이나 에너지 대사과정 등을 
조절한다. DBC1은 앞서 언급한 SIRT1의 주요한 억제자이다. 세포에 
스트레스가 가해진 환경에서는 DBC1은 SIRT1에 결합하여 SIRT1과 
결합하고 있던 p53을 떼어내어 아세틸화를 유도하며 p53의 전사활성을 
높여주어 하위 단계로 알려진 BAX, PUMA와 같은 세포사멸 유도 
유전자들의 전사를 활성화하게 된다. 하지만 어떻게 DBC1이 SIRT1에 
결합하여 조절되는지에 대해서는 밝혀진 것이 없다.  
DBC1의 인산화는 DBC1과 SIRT1간의 결합에 영향을 주고 SIRT1의 
탈아세틸화 기능을 조절한다. Etoposide와 산화 스트레스가 가해졌을 시, 
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ATM/ATR 인산화효소가 DBC1의 454번째 Thr기를 인산화한다. 
DBC1의 인산화는 SIRT1을 억제하고, p53의 아세틸화를 유도하여 p53에 
의해 매개되는 세포사멸을 유도한다. 하지만 DBC1의 인산화 유사 
돌연변이는 그 효과가 미미하다고 보고된 바 있다.  
본 연구에서는 DBC1이 SUMO의 표적단백질임을 확인하고, 591번째 
Lys기가 SUMO가 결합하는 위치임을 확인하였다. 또한 etoposide나 
doxorubicin 처리에 의해 스트레스 상황이 유도되면 DBC1의 수모화가 
유도됨을 보았으며, 이는 SUMO1이 아닌 SUMO2/3에 의한 것임을 
밝혔다. DBC1의 수모화는 DBC1과 SIRT1간의 결합을 증가시켜주며, 
p53의 아세틸화를 유도하는 것도 확인하였다.  
DBC1의 특이적인 SUMO E3결합효소는 PIAS3, 탈수모화효소는 
SENP1임을 확인하였다. PIAS3와 SENP1은 DBC1 내의 같은 지역에 
경쟁적으로 결합한다. Etoposide는 DBC1과 SENP1간의 결합을 
감소시키고, PIAS3와의 결합을 증가시킴으로써 DBC1의 수모화를 
증가시킨다. 앞선 실험 결과를 통해, ATM/ATR 인산화효소에 의한 
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DBC1의 인산화가 SENP1, PIAS3와 DBC1간의 결합에 상반된 영향을 
줌으로써 DBC1의 수모화를 조절한다는 것을 확인하였다. 또한, SENP1 
knockdown하였을 시, etoposide에 의한 세포사멸과정이 증가하고, 
반대로 PIAS3와 SUMO2/3를 knockdown하거나, DBC1의 수모화가 
유도되지 못하는 돌연변이를 과발현하였을 경우에는 세모사멸이 감소된다. 
이 모든 결과를 통해, SUMO2/3에 의한 DBC1의 수모화가 p53에 의해 
매개되는 세포사멸에 중요한 역할을 한다고 결론 내렸다. 
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